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Biliverdin-IX 0 reductase in human erythrocytes has been studied as NADPH-methemoglobin 
reductase at first, and then as NADPH-flavin reductase, or green-heme binding protein. At last, it 
was identified to be same with biliverdin-IX p reductase based on the amino acid sequence and base 
sequence of the cDNA. However, for the patients of hereditary methemogiobinemia, in which the 
main methemoglobin reductasing enzyme, NADH-cytochrome b5 reductase is deficient, the NADPH-
flavin reductase activity is indispensable for their lives. This paper summarized the history of the 
studies on the enzyme* 
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Hemoglobin in human erythrocytes binds oxygen and transports oxygen to various tissues, but always 
some part of hemoglobin is oxidized to non-functional hemoglobin, methemoglobin. In erythrocytes, there 
are two methemoglobin reducing enzyme systems, NADH- and NADPH-methemoglobin reductases to 
reduce back the methemoglobin produced to functional (oxy)hemoglobin. The former NADH-
methemoglobin reductase is the major enzyme, and the latter one is minor in function. In the case of 
deficiency of the major enzyme, the patients have the hereditary methemogiobinemia, and suffered from 
cyanosis in mild cases, or mental retardation and neurological impairments in severe cases. In those cases, 
the minor enzyme is considered to save the patient life functioning as the salvage enzyme to reduce the 
methemoglobin. However, the NADPH-methemoglobin reductase is not always sufficient to support the 
patient life. 
Gibson (1948) first described the deficiency of methemoglobin reducing enzyme in human erythrocytes 
as one of the responsible enzyme to cause human disease, and since then studies on NADH- and NADPH-
methemoglobin reductases have been done by many researchers. However, properties of the enzymes were 
not clarified for a long time until the major methemoglobin reducing enzyme system was identified clearly 
by Hultquist and Passon (1971) to be the electron transfer system of the soluble forms of NADH-
cytochrome bs reductase and cytochrome bs in erythrocytes. They showed that NADH-cytochrome bs 
reductase reduces cytochrome bs, and then the enzymatically reduced cytochrome bs reduces non-
enzymatically methemoglobin rapidly to functional oxyhemoglobin. 
In normal human erythrocytes, methemoglobin concentration is maintained to be less than 1% of total 
hemoglobin mainly by NADH-cytochrome bs and cytochrome b5. Function of the minor methemoglobin 
reducing enzyme, NADPH-methemoglobin reductase was also not unclear for long time, because in the 
patient erythrocytes with hereditary methemogiobinemia, in which NADH-cytochrome b5 reductase is 
deficient, methemoglobin is often accumulated up to around 30%, even though NADPH-methemoglobin-
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reducing enzyme exists sufficiently in the cells. NADPH-methemoglcbin reductase, in fact, cannot reduce 
™etSubin dirCCtIy " StUdied by tn VitW exPeriments- To characterize the physiological function of the NADPH-methemoglobin-reducing enzyme, many research groups tried to purify the enzyme from 
human erythrocytes, but those were almost hampered with contamination of hemoglobin and were 
unsuccessful. ' 
We have succeeded in purifying the enzyme from human erythrocytes, and found that flavins are 
effective electron earners among the physiological substances so far tested (FMN, FAD, riboflavin heroin 
GSSG) (Yubisui et al, 1976) to reduce methemoglobin, and named the enzyme NADPH-flavin reductase 
(Yubisu, et al, 1976; Yubisui et al., 1979). In the in vitro experiments, the purified enzyme reduced FMN 
or FAD, and then the reduced form of flavins transferred electron to methemoglobin nonenzymatically to 
reduce to oxyhemoglobin (Yubisui et al., 1979), and the reaction was analyzed to be very fast by the 
stopped-flow experiments (Yubisui et al, 1980). The rate constant for the reduction of methemoglobin by 
reduced FMN was determined to be 3.3 x 10" M" W at 25"C. This value is extremely high than the 
reduction rate of methemoglobin with ascorbic acid (1.8 x 10"J M'min1) (Yubisui et al., 1980) As 
described above, the purified enzyme did not reduce methemoglobin directly, but can reduce effectively via 
flavin. Based on these results, we confirmed that riboflavin added to intact human erythrocytes, reduced 
effectively methemoglobin to oxyhemoglobin by in vitro experiments (Matsuki et a/,,1978). 
Then, oral administration of riboflavin to patients with hereditary mefhemoglobinemia was tried to 
reduce methemoglobin in their erythrocytes, and the treatment was found to be effective (Matsuki et 
at.,1978, Kaplan and Chirouze, 1978), although the reduction of methemoglobin in patient erythrocytes 
was not so fast as compared with methylene blue (Goluboff and Wheaton, 1961). Methylene blue has long 
been used to reduce patient's methemoglobin in emergency, but the injection of the blue dye was 
unpleasant for patients, as their urine becomes blue. Contrary to this, flavins are the physiological 
substances and do not give any side effect to patients. Thus, NADPH-methemoglobin-reducing enzyme was 
called NADPH-flavin reductase, and the oral administration of flavin to patients was accepted as the 
general and effective therapeutics. 
DeFilippi and Hultquist (1978) purified previously a green-heme binding protein from bovine 
erythrocytes. The structure and function of the green-heme, named by them was unidentified to any known 
heme. Later, m the process to purify the green-heme binding protein, they tried to reduce the bound heme 
with NADPH-flavin reductase of bovine erythrocytes, as the heme bound to the protein was unstable in the 
oxidized form (1991). Following the purification procedure of Yubisui et al. (1976, 1979) to purify the 
NADPH.flavin reductase from bovine erythrocytes, they found that the behaviors of the enzyme during 
purification are very similar to their green-heme binding protein (Quandt et al., 1991). Then they analyzed 
the primary structures of both the purified green-heme binding protein and NADPH-flavin reductase and 
found that both of them are very similar to each other (Quandt et al, 1991) as shown in Fig. 1. 
After their report (Quandt et al, 1991), we cloned a cDNA for human reticulocyte NADPH-flavin 
reductase (Chikuba et al, 1994). The cDNA we cloned from a human reticulocyte cDNA library was 
consisted of about 800 bp with 621 bp coding-sequence, which encodes 206 amino acid residues and a 
polyadenylation signal in the 3'-noncoding region. The amino acid sequence deduced from the base 
sequence of the cDNA matched well with the partial amino acid sequences of peptides prepared from the 
flavin reductase purified from human erythrocytes (Chikuba et al, 1994). 
On the other hand, Yamaguchi et al. have been studied on the bilirubin metabolism in human tissues 
They punfxed biliverdin-IXp reductase from human liver and analyzed the primary structure of the enzyme 
(Yamaguchi et al, 1993). Their amino acid sequence determined was almost identical with that of our 
NADPH-flavin reductase except that the liver enzyme Jacks the N-terminal methionine and the C-terminaJ 
glutamine (Fig. 1). 
We subsequently expressed the recombinant human NADPH-flavin reductase in E. coli using the cloned 
cDNA to analyze whether our enzyme has the biliverdin-IXp- reductase activity (Chikuba et al, 1999). The 













Figure 1. The alignment of atnino add sequences of flavin reductases and biliverdin-IXp reductase. 
The upper sequence is the airrino acid sequence of human erytbrocyte flavin reductase (HumFR), the middle 
one is that of human liver biliverdin-IXp reductase (HumBR), and the bottom one is that of bovine erythrocyte 
flavin reductase (BovFR). Ami no acid sequence data was obtained from the database, HumFR and HumBR 
(P30043), and BovFR (P52556). 
recombinant human NADPH-flavin reductase showed significant biliverdin-IXp reductase activity with 
apparent Km values of 0.4 \xM for NADPH and 0.3 \iM for biliverdin-IXp, respectively, and the enzyme 
did not reduce biliverdin-IXa isomer (Chikuba et aL, 1999) as shown in Table 1. The Km value determined 
for biliverdin-IXp is a quite low value against the high Km value of 50 |xM for FMN (Yubisui et aL, 1976; 
Yubisui et aL, 1979). Therefore, the biliverdin-IXp reductase activity is more plausible and physiological 
activity of the enzyme in human erythrocytes rather than that of the flavin reductase activity. The cellular 
concentration of the free flavin in erythrocytes is quite low (less than 1 jiM); therefore, the enzyme cannot 
play a role practically as the flavin reductase in erythrocytes without externally added flavin. In the case of 
oral administration of ribbflavin to patients with hereditary methemoglobinemia, however, the flavin 
incorporated in the patient erythrocytes activates the reduction of methemoglobin to save the patient life 
(Matsuki et aL, 1978; Kaplan and Chirouze, 1978). 
Table 1. Enzyme activities of human flavin reductase and kinetic properties. 
Electron Concentrations Enzyme activity Km 
acceptors (M-M) (nmol/min/mg) 
a. Purified from human erythrocytes. 
b. Km value for NADPH of the FMN reductase activity. 
c. Not detectable. 
d. Km value for NADPH of the biliverdin-IXp reductase activity. 
A part of hemoglobin in erythrocytes is always oxidized to methemoglobin by loosing one electron 
from the heme in hemoglobin by chance accompanying the release of oxygen from the heme. The released 
oxygen with one electron becomes superoxide, and this superoxide may cleave the heme methen-bridge to 
biliverdin, the tetrapyrole compound. As another case to cause methemoglobin, some drugs we took also 
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oxidize hemoglobin, and some parts of the oxidized hemoglobin (methemoglobin) are degraded to bilirubin. 
NADPH-flavin reductase (biliverdin IXp reductase) may function to reduce biliverdin-IXp isomeiv Usually 
in Iranian liver cells, the a-methen-bridge of free heme is cleaved by heme oxygenase to produce 
biliverdin-IXa, but in human erythrocytes the major biliverdin-IX isomer was analyzed to be the p-form 
(94%), and the a-form (6%) was rather a minor one by Yamaguchi et al. (1994). At present we have no 
evidence to show the presence of heme oxygenase in erythrocytes to produce biliverdin. However, 
superoxide anion as described above, and also other unknown mechanism may cleave the heme, and in fact, 
the analyzed data (Yamaguchi et aL, 1994) shows that the biliverdin-IXp is predominant (94%) in human 
erythroeytes. 
Crystal structures of biliverdin-IXp and -a reductases to reduce these isomers were already analyzed, 
and those structures are clearly different from each other (Pereira^ a/., 2001; Whitby et aL, 2002). The 
structure of the biliverdin-IXp reductase revealed that it binds the p-isomer, and discriminates against the 
a-isomer through steric hindrance at the.binding pocket (Pereira et aL, 2001). 
This review summarized briefly the interesting history on the studies of biliverdin-IXp reductase in 
human erythrocytes. The enzyme was first called NADPH-methemoglobin reductase, but was later 
identified as NADPH-flavin reductase. The enzyme works well as NADPH-flavin reductase to reduce 
methemoglobin in patient erythrocytes to save their lives with oral administration of flavin. The identical 
enzyme in bovine erythoryctes, was studied as the green-heme binding protein (Quandt et aL, 1991), but 
was later identified as flavin reductase. Xu et al. (1993) reported that pyrroloquinoline quinone acts with 
flavin reductase to reduce ferryl myoglobin in vitro and protects isolated heart from re-oxygenation injury, 
but the physiological concentration of pyrroloquinoline quinone in cells is very low to function. 
Based on the kinetic studies on the recombinant flavin reductase, the most reasonable physiological 
function of the enzyme in human erythrocytes was concluded at last to be biliverdin-IXp reductase activity. 
However, the function of the NADPH-flavin reductase as a methemoglobin-reducing enzyme in 
erythrocytes is an indispensable activity for the patients with hereditary methemoglobinemia to maintain 
their lives. Thus, this enzyme can acts multifunctionally depending on the physiological conditions. 
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